Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Sosei opens phase I trial of CGRP receptor antagonist HTL-0022562

June 23, 2021

DTx Pharma presents new compounds for DMD

June 23, 2021

Neurona Therapeutics to advance its neural network-rebalancing cell therapies

June 23, 2021

SIGMAR1 mRNA identified as biomarker of response in phase II study of blarcamesine

June 21, 2021

NIH grant supports Praetego's development of AGE inhibitors

June 21, 2021

Canopy Growth divulges new cannabinoid CB1 and CB2 receptor modulators

June 21, 2021

Targeting FKBP5 lowers huntingtin levels by inducing autophagy in Huntington's disease models

June 21, 2021

Alnylam Pharmaceuticals divulges ATXN3-targeting ds-siRNAs

June 18, 2021

Satsuma reports phase I safety and PK data on STS-101

June 18, 2021

Akaal reports preclinical data on AK-119 in neuropathic pain

June 18, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 20, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...